Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations

BMC Psychiatry

Andrea Rossi¹  Roberta Rossi²  Sonia Frediani³  Giuseppe Rossi² 

[1] Medical Dept. Eli Lilly Italy, Via Gramsci 731, Sesto Fiorentino (FI), Italy;U.O. Psichiatria, IRCCS “Centro San Giovanni di Dio” Fatebenefratelli, via Pilastroni 4, Brescia, Italy;Centro di Salute Mentale La Badia U.S.L. 11, Empoli, Italy

关键词: Review;    Patients;    Schizophrenia;    Antipsychotic agents;    Delayed-action preparations;   

Others  :  1124309
DOI  :  10.1186/1471-244X-12-122

 received in 2011-12-15, accepted in 2012-08-01,  发布年份 2012

【 摘 要 】

Background

Current guidelines suggest specific criteria for oral or long-acting injectable antipsychotic drugs (LAIs). This review aims to describe the demographic and clinical characteristics of the ideal profile of the patient with schizophrenia treated with LAIs, through the analysis of nonrandomized studies.

Methods

A systematic review of nonrandomized studies in English was performed attempting to analyze the factors related to the choice and use of LAIs in daily practice. The contents were outlined using the Cochrane methods for nonrandomized studies and the variables included demographic as well as clinical characteristics. The available literature did not allow any statistical analysis that could be used to identify the ideal profile of patients with schizophrenia to be treated with LAIs.

Results

Eighty publications were selected and reviewed. Prevalence of LAI use ranged from 4.8% to 66%. The only demographic characteristics that were consistently assessed through retrieved studies were age (38.5 years in the 1970’s, 35.8 years in the 1980’s, 39.3 years in the 1990’s, to 39.5 years in the 2000’s) and gender (male > female).

Efficacy was assessed through the use of various symptom scales and other indirect measurements; safety was assessed through extrapyramidal symptoms and the use of anticholinergic drugs, but these data were inconsistent and impossible to pool. Efficacy and safety results reported in the different studies yielded a good therapeutic profile with a maximum of 74% decrease in hospital admissions and the prevalence of extrapyramidal symptoms with LAIs consistently increased at 6, 12, 18, and 24 months (35.4%, 37.1%, 36.9%, and 41.3%, respectively).

Conclusions

This analysis of the available literature strongly suggests that further observational studies on patients with schizophrenia treated with LAIs are needed to systematically assess their demographic and clinical characteristics and the relationships between them and patient outcome.

Besides the good efficacy and safety profile of LAIs, health care staff must also take into account the importance of establishing a therapeutic alliance with the patient and his/her relatives when selecting the most appropriate treatment. LAIs seem to be a good choice not only because of their good safety and efficacy profile, but also because they improve compliance, a key factor to improving adherence and to establishing a therapeutic alliance between patients with schizophrenia, their relatives, and their health care providers.

【 授权许可】

   
2012 Rossi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2 .

Figure 3 .

【 参考文献 】

• [1]Epi Database®: Kantar Health. Available from http://www.epidb.com. webcite Accessed 20 Jul 2011
• [2]Davis JM: Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975, 132:1237-1245.
• [3]Schooler NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003, 64:14-17.
• [4]Knapp M: Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl 2000, 407:15-18.
• [5]McEvoy JP: The costs of schizophrenia. J Clin Psychiatry 2007, 68(Suppl 14):4-7.
• [6]Law WL, Hui HY, Young WM, You JHS: Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients–a cost analysis. Int J Clin Pharmacol Ther 2007, 45:264-270.
• [7]Dernovsek MZ, Prevolnik Rupel V, Rebolj M, Tavcar R: Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry 2001, 16:474-482.
• [8]Larsen EB, Gerlach J: Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996, 93:381-388.
• [9]Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U: The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ 2010, 11:585-594.
• [10]Knapp MRJ: Measuring the economic benefit of treatment with atypical antipsychotics. Eur Psychiatry 1998, 13(Suppl 1):37s-45s.
• [11]Ahn J, McCombs JS, Jung C, Croudace TJ, McDonnell D, Ascher-Svanum H, Edgell ET, Shi L: Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 2008, 11:48-56.
• [12]Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M: Dose response of phrophylactic antipsychotics. J Clin Psychiatry 1993, 54:24-30.
• [13]Davis JM, Matalon L, Wantanabe MD, Blake L, Matalon L: Depot antipsychotic drugs. Place in therapy. Drugs 1994, 47:741-773.
• [14]Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001, 158:1835-1842.
• [15]Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca PM: Direct transition to long-acting risperidone–analysis of long-term efficacy. J Psychopharmacol 2005, 19:15-21.
• [16]Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antiphsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002, 159:103-108.
• [17]Correl CU, Cañas S, Larmo I, Levy P, Montes JM, Fagiolini A, Papageorgiou G, Rossi A, Sturlason R, Zink M: Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry 2011, 26:3-16.
• [18]David AS: Treatment adherence in psychoses. Br J Psychiatry 2010, 197:431-432.
• [19]Kane JM: Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003, 64:34-40.
• [20]Keith SJ, Kane JM: Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003, 64:1308-1315.
• [21]Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002, 63:1121-1128.
• [22]Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006, 67:1948-1953.
• [23]Leucht S, Heres S: Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006, 67:3-8.
• [24]Leucht S: Psychiatric treatment guidelines: doctors’ non-compliance or insufficient evidence? Acta Psychiatr Scand 2007, 115:417-419.
• [25]Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, David AS: Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010, 24:1473-1482.
• [26]Jaeger M, Rossler W: Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010, 175:58-62.
• [27]Hovens JE, Roman B, Van Dinther R: Patients with schizophrenia prefer long-acting injections. Schizophr Res 2006, 81(Suppl):S84.
• [28]Kikkert MJ, Schene AH, Koeter MWJ, Robson D, Born A, Helm H, Nose M, Goss C, Thornicroft G, Gray RJ: Medication adherence in schizophrenia: exploring patients’, carers’ and professionals’ views. Schizophrenia Bull 2006, 32:786-794.
• [29]McEvoy JP, Freter S, Everett G, Geller JL, Appelbaum P, Apperson LJ, Roth L: Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis 1989, 177:48-51.
• [30]McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, Geller JL, Roth L: Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis 1989, 177:43-47.
• [31]Buchanan A: A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992, 22:787-797.
• [32]David A, Buchanan A, Reed A, Almeida O: The assessment of insight in psychosis. Br J Psychiatry 1992, 161:599-602.
• [33]Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark SC, Gorman JM: Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 1994, 51:826-836.
• [34]Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC: Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007, 21:129-141.
• [35]Bartkó G, Mayláth E, Herczeg I: Comparative study of schizophrenic patients relapsed on and off medication. Psychiatry Res 1987, 22:221-227.
• [36]Heres S, Schmitz FS, Leucht S, Pajonk FG: The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007, 22:275-282.
• [37]McEvoy JP, Applebaum PS, Apperson LJ, Geller JL, Freter S: Why must some schizophrenic patients be involuntarily committed? The role of insight. Compr Psychiatry 1989, 30:13-17.
• [38]Kane JM, Mayerhoff D: Do negative symptoms respond to pharmacological treatment? Br J Psychiatry Suppl 1989, 7:115-118.
• [39]Tattan TM, Creed FH: Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001, 27:149-155.
• [40]Sellwood W, Tarrier N: Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994, 29:172-177.
• [41]Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
• [42]Xiang YT, Want CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Shinfuku N, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N: Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: findings of the Research on Asia Psychotropic Prescription (REAP) studies. Aust NZ J Psychiatry 2011, 45:193-198.
• [43]Pristach CA, Smith CM: Medication compliance and substance abuse among schizophrenic patients. Hosp Community Psychiatry 1990, 41:1345-1348.
• [44]Sim K, Su HC, Fujii S, Yang SY, Chong MY, Si T, Ling He Y, Kee Chung E, Huak Chan Y, Shinfuku N, Hoon Tan C, Ungvari G, Baldessarini RJ: Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. Int J Neuropsychopharmacol 2009, 12:117-123.
• [45]Valenstein M, Copeland L, Owen R, Blow F, Visnic S: Delays in adopting evidence-based dosages of conventional antipsychotics. Psychiatr Serv 2001, 52:1242-1244.
• [46]Conley RR, Kelly D, Love RC, McMahon RP: Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003, 15:23-31.
• [47]Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR: Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007, 58:482-488.
• [48]Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S: Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000, 61:344-348.
• [49]Green BN, Johnson CD, Adams A: Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Sports Chiropract Rehab 2001, 15:5-19.
• [50]Reeves BC, Deeks JJ, Higgins JPT, Wells GA: The Cochrane Non-Randomised Studies Methods Group: Including non-randomized studies. In Cochrane Handbook for Systematic Reviews of Interventions. 501st edition. Edited by Higgins JPT, Green S. West Sussex: John Wiley & Sons, Ltd; 2011:13.1-13.34.
• [51]Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group: Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000, 283:2008-2012.
• [52]Brugnoli R, Novick D, Belger M, Brown J, Germani S, Donda P, Rossi A, Pancheri P, The Italian SOHO Study Group: Effectiveness of antipsychotic treatment for schizophrenia: Italian results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study after 12 months. Giorn Ital Psicopat 2006, 12:283-292.
• [53]Brugnoli R, Novick D, Frediani S, Rossi A, Suarez D, Haro JM, The Italian SOHO Study Group: Efficacy of antipsychotic treatment in schizophrenia: results after 24 months in Italian patients in the Schizophrenia Outpatient Health Outcomes (SOHO) study. Giorn Ital Psicopat 2007, 13:330-340.
• [54]Ciudad A, Haro JM, Alonso J, Bousoño M, Suárez D, Novick D, Gilaberte I: The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry 2008, 23:1-7.
• [55]Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB; SOHO Study Group: The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand Suppl 2003, 107:7-15.
• [56]Novick D, Haro JM, Suarez D, Vieta E, Naber D: Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Res 2009, 108:223-230.
• [57]Lindström E, Wilderlöv B, von Knorring L: Antipsychotic drugs-a study of the prescription pattern in a total sample of patients with a schizophrenic syndrome in one catchment area in the county of Uppland, Sweden, in 1991. Int Clin Psychopharmacol 1996, 11:241-246.
• [58]Sim K, Su A, Ungvari GS, Fujii S, Yang SY, Chong MY, Si T, Chung EK, Tsang HY, Chan YH, Shinfuku N, Tan CH: Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol 2004, 19:103-109.
• [59]Owen R, Fischer EP, Kirchner JAE, Thrush CR, Williams DK, Cuffel BJ, Elliott CE, Booth BM: Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual 2003, 18:140-146.
• [60]Bitter I, Chou JC, Ungvari GS, Tang WK, Xiang Z, Iwanami A, Elliott CE, Booth BM: Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 2003, 36:143-149.
• [61]Chong SA, Sachdev P, Mahendran R, Chua HC: Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust NZ J Psychiatry 2000, 34:988-991.
• [62]Mamo DC, Sweet RA, Chengappa KNR, Reddy RR, Jeste DV: The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatric Psychiatry 2002, 17:1012-1017.
• [63]Remington G, Shammi CM, Sethna R, Lawrence R: Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psychiatr Serv 2001, 52:96-98.
• [64]Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008, 28:210-213.
• [65]Heres S, Reichhart T, Hamann J, Mendel R, Leucht S, Kissling W: Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 2011, 26:297-301.
• [66]Patel MX, Nikolaou V, David AS: Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003, 33:83-89.
• [67]Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO: Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines: Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004, 161:1-56.
• [68]Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006, 7:5-40.
• [69]Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, Kissling W: Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1987-1993.
• [70]Frank AF, Gunderson JG: The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990, 47:228-236.
• [71]Gharabawi GM, Lasser RA, Bossie CA, Zhu Y, Amador X: Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int Clin Psychopharmacol 2006, 21:233-240.
• [72]Stankovic Z, Britvic D, Vukovic O, Ille T: Treatment compliance of outpatients with schizophrenia: patient’s attitudes, demographic, clinical and therapeutic variables. Psychiatr Danub 2008, 20:42-52.
• [73]Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
• [74]Pinikahana J, Happell B, Taylor M, Keks NA: Exploring the complexity of compliance inschizophrenia. Issues Ment Health Nurs 2002, 23:513-528.
• [75]Mackay K, Taylor M, Patel MX: Medication adherence and patient choice in mental health. Br J Hosp Med (Lond) 2011, 72:6-7.
• [76]Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997, 23:637-651.
• [77]Heyscue BE, Levin GM, Merrick JP: Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998, 49:1232-1234.
• [78]Garavan J, Browne S, Gervin M, Lane A, Larkin C, O’Callaghan E: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998, 39:215-219.
• [79]Forkmann T, Scherer A, Boecker M, Pawelzik M, Jostes R, Gauggel S: The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome. BMC Psychiatry 2011, 11:83. BioMed Central Full Text
• [80]Remington G, Khramov I: Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:363-369.
• [81]Kazi HA: An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica 1986, 4:555-560.
• [82]Knudsen P, Hansen LB, Hojholdt K, Larsen NE: Long-term depot neuroleptic treatment with perphenazine decanoate II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand Suppl 1985, 322:41-50.
• [83]Knudsen P, Hansen LB, Hojholdt K, Larsen NE: Long-term depot neuroleptic treatment with perphenazine decanoate I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand Suppl 1985, 322:29-40.
• [84]Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER: Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005, 19:32-38.
• [85]Ganesan S, McKenna M, Procyshyn RM, Zipursky S: Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: a retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). Curr Therapeutic Res 2007, 68:409-420.
• [86]Mortimer AM: Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl 2007, 191:S7-S14.
• [87]Obermeier M, Schennach-Wolff R, Meyer S, Moller HJ, Riedel M, Krause D, Seemüller F: Is the PANSS used correctly? a systematic review. BMC Psychiatry 2011, 11:113. BioMed Central Full Text
• [88]Mauri MC, Turner M, Volonteri LS, Medori R, Maier W: Dosing patterns in Europe: efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. Int J Psychiatry Clin Pract 2009, 13:36-47.
• [89]Lasser RA, Bossie CA, Gharabawi GM, Kane JM: Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophrenia Res 2005, 77:215-227.
• [90]Jørgensen A, Aaes-Jørgensen T, Gravem A, Amthor KF, Dencker SJ, Rosell I, Baastrup PC, Buckhave J, Gram LF: Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology (Berl) 1985, 87:364-367.
• [91]Llorca PM, Bouhours P, Moreau-Mallet V, French Investigators Group: Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale 2008, 34:170-178.
• [92]Kim B, Lee SH, Choi TK, Suh SY, Kim YW, Yook KH, Lee EH: Effectiveness of a combined therapy of long-acting injectable risperidone and psychosocial intervention for relapse prevention in patients with schizophrenia. Clinical Psychopharmacology and Neuroscience 2008, 6:31-37.
• [93]Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijero R, Lex A, Latif MA, Medori R: Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007, 40:257-263.
• [94]Lee MS, Ko YH, Lee SH, Seo YJ, Kim SH, Joe SH, Han CS, Lee JH, Jung IK: Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006, 21:399-407.
• [95]Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R: Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005, 19:22-31.
• [96]Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM: Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry 2007, 19:65-71.
• [97]Beauclair L, Chue P, McCormick J, Camacho F, Lam A, Luong D: Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. J Med Econ 2007, 10:427-442.
• [98]Tavcar R, Dernovsek MZ, Zvan V: Chosing antipsychotic maintenance therapy - a naturalistic study. Pharmacopsychiatry 2000, 33:66-71.
• [99]Taylor M, Currie A, Lloyd K, Price M, Peperell K: Impact of risperidine long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008, 22:128-131.
• [100]Leal A, Rosillon D, Mehnert A, Jarema M, Remington G: Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004, 13:811-816.
• [101]Varner V, Hays JR, Wagner AL, Averill P: Outcome comparison of patients receiving oral or depot neuroleptic medication. Psychol Rep 2001, 89:169-174.
• [102]Haring C, Tegeler J, Lehmann E, Ptock WD: Social aspects of therapy with depot neuroleptics in the Federal Republic of Germany. Acta Psychiatr Belg 1981, 81:189-202.
• [103]Tegeler J, Lehmann E: A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Prog Neuropsychopharmacol 1981, 5:79-90.
• [104]Muirhead D, Harvey C, Ingram G: Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aust NZ J Psychiatry 2006, 40:596-605.
• [105]Denham J, Adamson L: Long-acting phenothiazines in the prevention of relapse of schizophrenic patients. Can Psychiatr Assoc J 1973, 18:235-237.
• [106]Kim SH, Jung DC, Ahn YM, Kim YS: The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. J Psychopharmacol 2010, 24:981-986.
• [107]Rössler W, Salize HJ, Reinhard I: Treatment with antipsychotics: the impact on the patient in the community. Eur Psychiatry 1998, 13:31s-36s.
• [108]Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333:224.
• [109]Soni SD, Gaskell K, Reed P: Factors affecting rehospitalization rates of chronic schizophrenic patients living in the community. Schizophrenia Res 1994, 12:169-177.
• [110]Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ: Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005, 8:427-438.
• [111]Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA: An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophrenia Res 2005, 77:129-139.
• [112]van Os J, Bossie CA, Lasser RA: Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004, 19:229-232.
• [113]Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008, 23:325-331.
• [114]Gaby N, Lefkowitz D, Israel R: Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients. N C Med J 1982, 43:641-644.
• [115]Hoiberg MP, Nielsen B: Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nord J Psychiatry 2006, 60:207-212.
• [116]Marchiaro L, Rocca P, LeNoci F, Longo P, Montemagni C, Rigazzi C, Bogetto F: Naturalistic, restrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. J Clin Psychiatry 2005, 66:1423-1431.
• [117]Ainsah O, Salmi R, Osman CB, Shamsul AS: Relationships between antipsychotic medication and anthropometric measurements in patients with schizophrenia attending a psychiatric clinic in Malaysia. Hong Kong J Psychiatry 2008, 18:23-27.
• [118]Deslandes PN, Thomas A, Faulconbridge GM, Davies WC: Experience with risperidone long-acting injection: results of a naturalistic observation study. Int J Psychiatry Clin Pract 2007, 11:207-221.
• [119]Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fenning S, Ratzoni G: Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001, 62:855-859.
• [120]Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, Ungvari GS, Si T, Chung EK, Tsang HY, Shinfuku N, Kua EH, Tan CH: High dose antipsychotic use in schizophrenia: findings from the REAP (Research on East Asia Psychotropic Prescriptions) Study. Pharmacopsychiatry 2004, 37:175-179.
• [121]Herrán A, García-Unzueta MT, Fernández-González MD, Vázquez-Barquero JL, Álvarez C, Amado JA: Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics. Psychiatry Res 2000, 94:51-58.
• [122]Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelkis S, Haro JM, Ratcliffe M, Hong J, Novick D, SOHO Study Group: Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO Study. PharmacoEconomics 2008, 26:341-358.
• [123]Marland GR, Sharkey V: Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. J Adv Nurs 1999, 30:1255-1262.
• [124]National Institute for Health and Clinical Excellence: The Guidelines Manual. London; 2011. [http://www.nice.org.uk webcite]
• [125]Kane JM, Aguglia E, Altamura AC, Ayuso Gutiérrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindström E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998, 8:55-66.
• [126]Keith SJ, Kane JM, Turner M, Conley RR, Narsallah HA: Academic highlights: Guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004, 65:120-131.
• [127]Kane JM, Garcia-Ribera C: Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009, 52:S63-S67.
• [128]Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005, 39:1-30.
• [129]Masand PS, Gupta S: Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003, 20:1099-1110.
• [130]Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003, 64:5-19.
• [131]National Collaborating Centre for Mental Health: Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. London, UK: National Institute for Health and Clinical Excellence (NICE); 2009:1-41. NICE clinical guideline No. 82
• [132]Ngoh LN: Health literacy: a barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc 2009, 49:e132-e146.
• [133]Charpentier A, Goudemand M, Thomas P: Therapeutic alliance, a stake in schizophrenia. Encephale 2009, 35:80-89.
• [134]Kerwin R: Connecting patient needs with treatment management. Acta Psychiatr Scand Suppl 2009, 438:33-39.
• [135]Sernyak MJ, Dausey D, Desai R, Rosenheck R: Prescribers’ nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv 2003, 54:246-248.
• [136]Kong DS, Yeo SH: An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica 1989, 5:371-379.
• [137]Gharabawi GM, Gearhart NC, Lasser RA, Mahmoud RA, Zhu Y, Mannaert E, Naessens I, Bossie CA, Kujawa M, Simpson GM: Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 2007, 6:3. BioMed Central Full Text
• [138]Walburn J, Gray R, Gournay K, Quraishi S, David AS: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001, 179:300-307.
• [139]Patel MX, de Zoysa N, Baker D, David AS: Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005, 12:237-244.
• [140]Přikry R, Kučerová HP, Vrzalová M, Cešková E: Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective. Schizophrenia Res Treat 2012., (Article ID 764769)
• [141]Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E, StoRMi Study Group: Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005, 20:121-130.
• [142]Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W: Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005, 19:5-14.
• [143]Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R: Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 2008, 46:14-22.
• [144]Haro JM, Novick D, Suarez D, Ochoa S, Roca M: Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1287-1292.